EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder

Riley E. Alexander, Rodolfo Montironi, Antonio Lopez-Beltran, Sean R. Williamson, Mingsheng Wang, Kristin M. Post, Joyashree D. Sen, Ashley K. Arnold, Shaobo Zhang, Xiaoyan Wang, Michael Koch, Noah M. Hahn, Timothy Masterson, Gregory T. MacLennan, Darrell Davidson, Eva Compérat, Liang Cheng

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The identification of mutations in epidermal growth factor receptor (EGFR) and translocations involving anaplastic lymphoma kinase (ALK) in lung adenocarcinoma has drastically changed understanding of the disease and led to the development of targeted therapies. Adenocarcinoma of the urinary bladder is rare and poorly understood at the molecular level. We undertook this study to determine whether EGFR mutations, increases in EGFR copy number, or ALK translocations are present in these tumors. Twenty-eight cases of primary bladder adenocarcinoma were analyzed. For EGFR mutational analysis, PCR-amplified products were analyzed on the Q24 Pyrosequencer with Qiagen EGFR Pyro Kits. All cases were analyzed via fluorescence in situ hybridization (FISH) using Vysis ALK Break Apart FISH Probes for detection of ALK chromosomal translocation and Vysis Dual Color Probes to assess for increased gene copy number of EGFR. None of the 28 cases examined showed mutational events in EGFR or ALK rearrangements. EGFR polysomy was seen in 10 out of 28 (36%) cases. No correlation with EGFR polysomy was seen in the tumors with respect to age, histologic subtypes, pathologic stage, or lymph node metastasis. In summary, EGFR mutations and ALK rearrangements do not appear to be involved in the development of primary adenocarcinoma of the urinary bladder. A subgroup of cases (36%), however, demonstrated increased gene copy number of EGFR by FISH.

Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalModern Pathology
Volume27
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Epidermal Growth Factor Receptor
Urinary Bladder
Adenocarcinoma
Fluorescence In Situ Hybridization
Gene Dosage
Mutation
anaplastic lymphoma kinase
Genetic Translocation
Neoplasms
Color
Lymph Nodes
Neoplasm Metastasis
Polymerase Chain Reaction

Keywords

  • adenocarcinoma
  • EML4-ALK rearrangement
  • epidermal growth factor receptor (EGFR)
  • gene copy number
  • polysomy
  • targeted therapy
  • urinary bladder

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. / Alexander, Riley E.; Montironi, Rodolfo; Lopez-Beltran, Antonio; Williamson, Sean R.; Wang, Mingsheng; Post, Kristin M.; Sen, Joyashree D.; Arnold, Ashley K.; Zhang, Shaobo; Wang, Xiaoyan; Koch, Michael; Hahn, Noah M.; Masterson, Timothy; MacLennan, Gregory T.; Davidson, Darrell; Compérat, Eva; Cheng, Liang.

In: Modern Pathology, Vol. 27, No. 1, 01.2014, p. 107-112.

Research output: Contribution to journalArticle

Alexander, RE, Montironi, R, Lopez-Beltran, A, Williamson, SR, Wang, M, Post, KM, Sen, JD, Arnold, AK, Zhang, S, Wang, X, Koch, M, Hahn, NM, Masterson, T, MacLennan, GT, Davidson, D, Compérat, E & Cheng, L 2014, 'EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder', Modern Pathology, vol. 27, no. 1, pp. 107-112. https://doi.org/10.1038/modpathol.2013.132
Alexander, Riley E. ; Montironi, Rodolfo ; Lopez-Beltran, Antonio ; Williamson, Sean R. ; Wang, Mingsheng ; Post, Kristin M. ; Sen, Joyashree D. ; Arnold, Ashley K. ; Zhang, Shaobo ; Wang, Xiaoyan ; Koch, Michael ; Hahn, Noah M. ; Masterson, Timothy ; MacLennan, Gregory T. ; Davidson, Darrell ; Compérat, Eva ; Cheng, Liang. / EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. In: Modern Pathology. 2014 ; Vol. 27, No. 1. pp. 107-112.
@article{cf4618150787438d89696191e1c9f696,
title = "EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder",
abstract = "The identification of mutations in epidermal growth factor receptor (EGFR) and translocations involving anaplastic lymphoma kinase (ALK) in lung adenocarcinoma has drastically changed understanding of the disease and led to the development of targeted therapies. Adenocarcinoma of the urinary bladder is rare and poorly understood at the molecular level. We undertook this study to determine whether EGFR mutations, increases in EGFR copy number, or ALK translocations are present in these tumors. Twenty-eight cases of primary bladder adenocarcinoma were analyzed. For EGFR mutational analysis, PCR-amplified products were analyzed on the Q24 Pyrosequencer with Qiagen EGFR Pyro Kits. All cases were analyzed via fluorescence in situ hybridization (FISH) using Vysis ALK Break Apart FISH Probes for detection of ALK chromosomal translocation and Vysis Dual Color Probes to assess for increased gene copy number of EGFR. None of the 28 cases examined showed mutational events in EGFR or ALK rearrangements. EGFR polysomy was seen in 10 out of 28 (36{\%}) cases. No correlation with EGFR polysomy was seen in the tumors with respect to age, histologic subtypes, pathologic stage, or lymph node metastasis. In summary, EGFR mutations and ALK rearrangements do not appear to be involved in the development of primary adenocarcinoma of the urinary bladder. A subgroup of cases (36{\%}), however, demonstrated increased gene copy number of EGFR by FISH.",
keywords = "adenocarcinoma, EML4-ALK rearrangement, epidermal growth factor receptor (EGFR), gene copy number, polysomy, targeted therapy, urinary bladder",
author = "Alexander, {Riley E.} and Rodolfo Montironi and Antonio Lopez-Beltran and Williamson, {Sean R.} and Mingsheng Wang and Post, {Kristin M.} and Sen, {Joyashree D.} and Arnold, {Ashley K.} and Shaobo Zhang and Xiaoyan Wang and Michael Koch and Hahn, {Noah M.} and Timothy Masterson and MacLennan, {Gregory T.} and Darrell Davidson and Eva Comp{\'e}rat and Liang Cheng",
year = "2014",
month = "1",
doi = "10.1038/modpathol.2013.132",
language = "English",
volume = "27",
pages = "107--112",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder

AU - Alexander, Riley E.

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

AU - Williamson, Sean R.

AU - Wang, Mingsheng

AU - Post, Kristin M.

AU - Sen, Joyashree D.

AU - Arnold, Ashley K.

AU - Zhang, Shaobo

AU - Wang, Xiaoyan

AU - Koch, Michael

AU - Hahn, Noah M.

AU - Masterson, Timothy

AU - MacLennan, Gregory T.

AU - Davidson, Darrell

AU - Compérat, Eva

AU - Cheng, Liang

PY - 2014/1

Y1 - 2014/1

N2 - The identification of mutations in epidermal growth factor receptor (EGFR) and translocations involving anaplastic lymphoma kinase (ALK) in lung adenocarcinoma has drastically changed understanding of the disease and led to the development of targeted therapies. Adenocarcinoma of the urinary bladder is rare and poorly understood at the molecular level. We undertook this study to determine whether EGFR mutations, increases in EGFR copy number, or ALK translocations are present in these tumors. Twenty-eight cases of primary bladder adenocarcinoma were analyzed. For EGFR mutational analysis, PCR-amplified products were analyzed on the Q24 Pyrosequencer with Qiagen EGFR Pyro Kits. All cases were analyzed via fluorescence in situ hybridization (FISH) using Vysis ALK Break Apart FISH Probes for detection of ALK chromosomal translocation and Vysis Dual Color Probes to assess for increased gene copy number of EGFR. None of the 28 cases examined showed mutational events in EGFR or ALK rearrangements. EGFR polysomy was seen in 10 out of 28 (36%) cases. No correlation with EGFR polysomy was seen in the tumors with respect to age, histologic subtypes, pathologic stage, or lymph node metastasis. In summary, EGFR mutations and ALK rearrangements do not appear to be involved in the development of primary adenocarcinoma of the urinary bladder. A subgroup of cases (36%), however, demonstrated increased gene copy number of EGFR by FISH.

AB - The identification of mutations in epidermal growth factor receptor (EGFR) and translocations involving anaplastic lymphoma kinase (ALK) in lung adenocarcinoma has drastically changed understanding of the disease and led to the development of targeted therapies. Adenocarcinoma of the urinary bladder is rare and poorly understood at the molecular level. We undertook this study to determine whether EGFR mutations, increases in EGFR copy number, or ALK translocations are present in these tumors. Twenty-eight cases of primary bladder adenocarcinoma were analyzed. For EGFR mutational analysis, PCR-amplified products were analyzed on the Q24 Pyrosequencer with Qiagen EGFR Pyro Kits. All cases were analyzed via fluorescence in situ hybridization (FISH) using Vysis ALK Break Apart FISH Probes for detection of ALK chromosomal translocation and Vysis Dual Color Probes to assess for increased gene copy number of EGFR. None of the 28 cases examined showed mutational events in EGFR or ALK rearrangements. EGFR polysomy was seen in 10 out of 28 (36%) cases. No correlation with EGFR polysomy was seen in the tumors with respect to age, histologic subtypes, pathologic stage, or lymph node metastasis. In summary, EGFR mutations and ALK rearrangements do not appear to be involved in the development of primary adenocarcinoma of the urinary bladder. A subgroup of cases (36%), however, demonstrated increased gene copy number of EGFR by FISH.

KW - adenocarcinoma

KW - EML4-ALK rearrangement

KW - epidermal growth factor receptor (EGFR)

KW - gene copy number

KW - polysomy

KW - targeted therapy

KW - urinary bladder

UR - http://www.scopus.com/inward/record.url?scp=84891746850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891746850&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2013.132

DO - 10.1038/modpathol.2013.132

M3 - Article

VL - 27

SP - 107

EP - 112

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 1

ER -